← Back to Search

CRISPR-Cas9 Inhibitor

Cohort 3 for Bloodstream Infection

Phase 1
Waitlist Available
Research Sponsored by SNIPR Biome Aps.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Normal defecation pattern (at least once daily)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 187 days
Awards & highlights

Study Summary

This trial is testing a new drug to see if it is safe and effective. It is given to healthy participants to test the safety, tolerability, and how the body processes the drug.

Eligible Conditions
  • Bloodstream Infection
  • E. coli Infections

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You usually have a bowel movement at least once a day.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~187 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 187 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety and tolerability as measured by incidence and severity of AEs and Medically Attended Adverse Events (MAAEs) from the first administration of study drug and up until Day 35 of the study.
Secondary outcome measures
Functional quantification of SNIPR001 (recovery) in feces, blood, and urine before, during, and after multiple oral SNIPR001 administrations
Incidence and severity of AEs and MAAEs from Day 35 to Day 187 of the study

Trial Design

3Treatment groups
Active Control
Group I: Cohort 3Active Control2 Interventions
12 participants on SNIPR001 (Dose 3 BID for 7 days) and 8 participants on placebo
Group II: Cohort 1Active Control2 Interventions
6 participants on SNIPR001 (Dose 1 BID for 7 days) and 2 participants on placebo
Group III: Cohort 2Active Control2 Interventions
6 participants on SNIPR001 (Dose 2 BID for 7 days) and 2 participants on placebo

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

SNIPR Biome Aps.Lead Sponsor
Biomedical Advanced Research and Development AuthorityFED
79 Previous Clinical Trials
908,847 Total Patients Enrolled
Wellcome TrustOTHER
213 Previous Clinical Trials
15,678,906 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment presently available for this clinical study?

"According to clinicaltrials.gov, the recruitment process for this trial, which was initially posted on March 24th 2022 and last modified on December 1st 2022, is now concluded. Nevertheless, there are 911 other medical studies currently enrolling participants across the globe right now."

Answered by AI

Does this research endeavor accept participants who are above the age of sixty?

"This study seeks individuals aged 18 and above, yet still under 65."

Answered by AI

Has the regulatory body approved Cohort 1 for commercial use?

"The safety of Cohort 1 has been estimated with a score of one due to the fact that this is an early-stage trial. Thus, there is limited evidence regarding its efficacy and safety."

Answered by AI

What type of volunteers is this research endeavor calling for?

"Candidates aged between 18 and 65 with escherichia coli infections are eligible to enroll in this clinical trial. Currently, the team is hoping to recruit 36 participants."

Answered by AI
~12 spots leftby Mar 2025